Adverse drug reactions caused by drug-drug interactions in elderly outpatients: A prospective cohort study

European Journal of Clinical Pharmacology

Volumn 68, Issue 12, 2012, Pages 1667-1676

  Obreli Neto, Paulo Roque ^a   Nobili, Alessandro ^b   De Oliveira Baldoni, André ^c   Guidoni, Camilo Molino ^c   De Lyra Jr , Divaldo Pereira ^d   Pilger, Diogo ^e   Duzanski, Juliano ^f   Tettamanti, Mauro ^b   Cruciol Souza, Joice Mara ^g   Gaeti, Walderez Penteado ^a   Cuman, Roberto Kenji Nakamura ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d FEDERAL UNIVERSITY OF SERGIPE   (Brazil)

^e FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^f Faculdades Integradas de Ourinhos   (Brazil)

^g STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Age; Cohort studies; Drug interactions; Drug toxicity; Outpatients; Pharmacovigilance

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; AMITRIPTYLINE; AMLODIPINE; ANTIINFECTIVE AGENT; ATENOLOL; BEZAFIBRATE; CAPTOPRIL; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CIPROFLOXACIN; CLOPIDOGREL; DICLOFENAC; DIGOXIN; ENALAPRIL; ERYTHROMYCIN; FLUOXETINE; FUROSEMIDE; GASTROINTESTINAL AGENT; GLIBENCLAMIDE; HEMATOLOGIC AGENT; HYDROCHLOROTHIAZIDE; LOSARTAN; METFORMIN; PIROXICAM; POTASSIUM SPARING DIURETIC AGENT; SIMVASTATIN; SPIRONOLACTONE; UNINDEXED DRUG; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRAZIL; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; DISEASE SEVERITY; DRUG CLASSIFICATION; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; ELDERLY CARE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYOPATHY; OUTPATIENT CARE; OVERANTICOAGULATION; PARKINSONISM; PHARMACODYNAMICS; POLYPHARMACY; POTASSIUM BLOOD LEVEL; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLIC HEALTH; RISK FACTOR; SEROTONIN SYNDROME; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VOMITING;

AGED; AMBULATORY CARE; BRAZIL; DRUG INTERACTIONS; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PROSPECTIVE STUDIES;

EID: 84871285571     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1309-3     Document Type: Article

References (49)

1. Hansten PD, Horn JR (2009) Drug interactions analysis and management. Facts & Comparisons. Lippincott Williams & Wilkins, Philadelphia
2. Cruciol-Souza JM, Thomson JC (2006) Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci 9:427-433
3. Obreli-Neto PR, Vieira JC, Teixeira DRA, Silva FP, Gaeti WP, Cuman RKN (2011) Potential risks in drug prescriptions to elderly: a cross-sectional study in the public primary health care system of Ourinhos micro-region, Brazil. Acta Farm Bonaerense 30:629-635
4. Björkman IK, Fastbom J, Schmidt IK, Bernsten CB, Pharmaceutical Care of the Elderly in Europe Research (PEER) Group (2002) Drugdrug interactions in the elderly. Ann Pharmacother 36:1675-1681. doi:10.1345/aph.1A484
5. Tulner LR, Frankfort SV, Gijsen GJ, van Campen JP, Koks CH, Beijnen JH (2008) Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging 25:343-355
6. Hamilton RA, Briceland LL, Andritz MH (1998) Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy 18:1112-1120
7. Shad MU, Marsh C, Preskorn SH (2001) The economic consequences of a drug-drug interaction. J Clin Psychopharmacol 21:119-120
8. Grymonpre RE, Mitenko PA, Sitar DS, Aoki FY, Montgomery PR (1998) Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc 36:1092-1098
9. Mangoni AA, Jackson SH (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6-14. doi:10.1046/j.1365- 2125.2003.02007.x
10. Mallet L, Spinewine A, Huang A (2007) The challenge of managing drug interactions in elderly people. Lancet 370:185-191. doi:10.1016/S0140-6736(07) 61092-7
11. Cusack BJ (2004) Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2:274-302. doi:10.1016/j.amjopharm.2004.12.005
12. Turnheim K (2003) When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 38:843-853. doi:10.1016/S0531- 5565(03)00133-5
13. Noble RE (2003) Drug therapy in the elderly. Metabolism 52:27- 30. doi:10.1016/S0026-0495(03)00298-114
14. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M (2009) Adverse drug reactions in hospital inpatients: a prospective analysis of 3695 patient-episodes. PLoS One 4:e4439. doi:10.1371/journal.pone.0004439
15. Reis AM, Cassiani SH (2011) Adverse drug events in an intensive care unit of a university hospital. Eur J Clin Pharmacol 67:625- 632. doi:10.1007/s00228-010-0987-y
16. República Federativa do Brasil (1990) Lei n. 8080, 19 de setembro de 1990. Dispõe sobre as condições para a promoção, proteção e recuperação da saúde, a organização e o funcionamento dos serviços correspondentes e dá outras providências. http://portal.in.gov.br/. Accessed 09 October 2010
17. República Federativa do Brasil (1990) Lei n. 8142, de 28 de dezembro de 1990. Dispõe sobre a participação da comunidade na gestão do Sistema Único de Saúde (SUS) e sobre as transferências intergovernamentais de recursos financeiros na área da saúde e dá outras providências. http://portal.in.gov.br/. Accessed 09 October 2010
18. United Nations Programme on Ageing (2010) The Ageing of the World's Population. http://www.un.org/ageing/popageing.html. Accessed 10 October 2010
19. World Health Organization (1984) The uses of epidemiology in the study of the elderly. World Health Organization, Geneva
20. DrugDigest (2010) Check interactions. http://www.drugdigest.org/ wps/portal/ddigest. Accessed 12 October 2010
21. Drugs (2010) Drug interaction checker. http://www.drugd.com/drug- interactions.html. Accessed 12 October 2010
22. Medscape (2010) Drug information. http://www.medscape.com/druginfo/ druginterchecker. Accessed 12 October 2010
23. Micromedex (2010) Micromedex healthcare series. http://www. periodicos.capes.gov.br/. Accessed 13 October 2010
24. Vonbach P, Dubied A, Krähenbühl S, Beer JH (2008) Evaluation of frequently used drug interaction screening programs. Pharm World Sci 30:367-374. doi:10.1007/s11096-008-9191-x
25. World Health Organization Collaborating Centre for Drug Statistics Methodology (2010)ATC/DDD Index. http://www.whocc.no/atcddd/. Accessed 15 October 2010
26. Karch FE, Lasagna L (1977) Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 21:247-254
27. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR (1979) An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA 242:623-632. doi:10.1001/jama.1979. 03300070019017
28. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239-245. doi:10.1038/clpt.1981. 154
29. Macedo AF, Marques FB, Ribeiro CF, Teixeira F (2003) Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel, according to different levels of imputability. J Clin Pharm Ther 28:137-143. doi:10.1046/j.1365-2710.2003.00475.x
30. Hartwig SC, Siegel J, Schneider PJ (1992) Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 49:2229-2232
31. Davies EC, Green CF, Mottram DR, Pirmohamed M (2006) Adverse drug reactions in hospital in-patients: a pilot study. J Clin Pharm Ther 31:335-341. doi:10.1111/j.1365-2710.2006.00744.x
32. Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, Seger DL, Shu K, Federico F, Leape LL, Bates DW (2003) Adverse drug events in ambulatory care. N Engl J Med 348:1556- 1564. doi:10.1056/NEJMsa020703
33. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383
34. Leone R, Magro L, Moretti U, Cutroneo P, Moschini M, Motola D, Tuccori M, Conforti A (2010) Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. Drug Saf 33:667-675. doi:10.2165/11534400-000000000-00000
35. Strandell J, Wahlin S (2011) Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database. Eur J Clin Pharmacol 67:633-641. doi:10.1007/s00228-010-0979-y
36. Hohl CM, Dankoff J, Colacone A, Afilalo M (2001) Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 38:666-671. doi:10.1067/mem.2001.119456
37. Pirmohamed M, James S, Meakin S, Green C, Scot AK, Walley TL, Farrar K, Park BK, Breckenridge AM(2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 329:15-19. doi:10.1136/bmj.329.7456.15
38. Shorr RI, Ray WA, Daugherty JR, Griffin MR (1993) Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants. Arch Intern Med 153:1665-1670
39. Hernández-Díaz S, Rodríguez LA (2000) Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 160:2093-2099
40. Perazella MA, Mahnensmith RL (1997) Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis. J Gen Intern Med 12:646-656. doi:10.1046/j.1525-1497.1997.07128.x
41. Schepkens H, Vanholder R, Billiouw JM, Lameire N (2001) Lifethreatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 110:438-441. doi:10.1016/S0002- 9343(01)00642-8
42. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD (2010) Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 33:171-187. doi:10.2165/11319380-000000000-00000
43. Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD (1984) Digitalis glycosides: mechanisms and manifestations of toxicity. Part I. Prog Cardiovasc Dis 26:413-458
44. Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD (1984) Digitalis glycosides: mechanisms and manifestations of toxicity. Part II. Prog Cardiovasc Dis 26:495-540
45. Sandson N (2005) Drug-drug interactions: the silent epidemic. Psychiatr Serv 56:22-24. doi:10.1176/appi.ps.56.1.22
46. Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC, Lipton RB (2003) Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc 44:136-141
47. Guidoni CM, Baldoni AO, Obreli-Neto PR, Pereira LRL (2011) Fontes de informações sobre interações medicamentosas: Há concordância entre elas? Rev Univ Vale Rio Verde 9:84-91. doi:10.5892/ruvrv.2011.92.8491
48. Vitry AI (2007) Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 63:709-714. doi:10.1111/j.1365- 2125.2006.02809.x
49. Caccia S, Garattini S, Pasina L, Nobili A (2009) Predicting the clinical relevance of drug interactions from pre-approval studies. Drug Saf 32:1017-1039. doi:10.2165/11316630-000000000-00000